Download GMP-Certified
API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.

A 92% success rate in curing FIP

The most effective FIP treatment strategy is GS-441524, generally known as just GS.

It has been shown to be 92% successful when the correct treatment protocols are followed. It produces quick results and has no unfavourable side effects. GS-441524 is a FIP antiviral molecule that has shown efficacy in treating feline coronavirus, irrespective of the severity and duration of symptoms. 

Several additional reports demonstrate the therapeutic efficacy of GS-441524 administered orally or by injection for the treatment of FIP. When GS-441524 is administered subcutaneously to cats with spontaneously occurring FIP, survival rates increase to 77% after six months. This does not apply to cats with ocular or severe neurologic forms, where medication penetration into the bloodstream is unknown and blood-brain and blood-eye is uncertain. 1, 2, and 2.

A safe treatment

GS-441524 has been proven to be a safe and successful treatment for the condition in cats, with the majority of clinical trials taking place in Australia and the UK.

The treatment with GS-441524 has remarkably few systemic side effects. In certain cats, it may result in mild kidney damage; however, overt renal illness does not develop from this. A few cats have experienced systemic medication reactions of the vasculitis variety, which are sometimes mistaken for injection site reactions.

Available as an injectable drug and oral formulation

Initially developed as an injectable drug, the transition to an oral formulation represents an important step in making GS-441524 a more feasible treatment modality for most cat owners. Contact us if you would like more information in regards to the difference between injections and oral tablets to determine what product is most suitable for your needs.

GS-441524 is now FDA-approved in several countries

For a number of years, many understandably frantic owners of FIP-infected cats in the United States sought this substance through unregulated and frequently untrustworthy black-market sources because it was not previously FDA-approved. This announcement offers a significant glimmer of hope in the treatment of a previously incurable and devastating feline disease, along with the FDA’s Centre for Veterinary Medicine’s (CVM) notification to veterinarians that compounded GS-441524 falls under Guidance for Industry #256 and is permitted to be compounded and lawfully prescribed.

Produced in a GMP facility

Today, the market is flooded with GS-441524. As a result, the important thing when buying the product is to ensure the GS-441524 is of the highest quality since this will directly affect the result of the treatment. 

At MedicaPharma we are committed to using only the finest materials and ingredients in our products, carefully avoiding any substances that could trigger allergic reactions in your cat. Our GS-441524 is therefore produced in a GMP facility. Several veterinary institutes in Europe use our raw materials with very good results. If you would like more information, references are available upon request.